» Authors » F Di Raimondo

F Di Raimondo

Explore the profile of F Di Raimondo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 125
Citations 1042
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Martino E, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, et al.
ESMO Open . 2025 Jan; 10(2):104084. PMID: 39778329
Background: Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large,...
2.
Giallongo C, Dulcamare I, Giallongo S, Duminuco A, Pieragostino D, Cufaro M, et al.
Cell Death Dis . 2023 Oct; 14(10):686. PMID: 37852977
Ineffective hematopoiesis is a hallmark of myelodysplastic syndromes (MDS). Hematopoietic alterations in MDS patients strictly correlate with microenvironment dysfunctions, eventually affecting also the mesenchymal stromal cell (MSC) compartment. Stromal cells...
3.
Mazzucco W, Chiara di Maio V, Bronte F, Fabeni L, Pipitone R, Grimaudo S, et al.
J Hosp Infect . 2021 Jun; 115:51-58. PMID: 34171407
Background: Occurrence of hepatitis C virus (HCV) infection is reduced by effective risk management procedures, but patient-to-patient transmission continues to be reported in healthcare settings. Aim: To report the use...
4.
Romano A, Parrinello N, Simeon V, Puglisi F, La Cava P, Bellofiore C, et al.
Sci Rep . 2020 Feb; 10(1):1983. PMID: 32029833
To understand neutrophil impairment in the progression from MGUS through active MM, we investigated the function of mature, high-density neutrophils (HDNs), isolated from peripheral blood. In 7 MM, 3 MGUS...
5.
Offidani M, Boccadoro M, Di Raimondo F, Petrucci M, Tosi P, Cavo M
Curr Hematol Malig Rep . 2019 May; 14(3):187-196. PMID: 31077067
Purpose Of Review: A working group of six expert physicians convened to assess the spectrum of multiple myeloma relapse presentations, discussed the features that can define the disease as aggressive...
6.
Giuffrida G, Nicolosi D, Rapisarda C, Calafiore V, Giuffrida A, Di Raimondo F
Haemophilia . 2018 Dec; 25(2):e135-e137. PMID: 30589157
No abstract available.
7.
Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, et al.
Leukemia . 2017 Sep; 32(3):654-662. PMID: 28935990
In chronic lymphocytic leukemia (CLL), stabilizing mutations of NOTCH1, affecting up to 10-15% of cases, have been associated to poor prognosis, disease progression and refractoriness to chemotherapy. NOTCH1 mutations are...
8.
Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi F, et al.
Leukemia . 2017 Mar; 31(11):2407-2415. PMID: 28321119
In chronic lymphocytic leukemia (CLL), the mechanisms controlling cell growth and proliferation in the presence of NOTCH1 mutations remain largely unexplored. By performing a gene expression profile of NOTCH1-mutated (NOTCH1-mut)...
9.
Ruggieri M, Pratico A, Serra A, Maiolino L, Cocuzza S, di Mauro P, et al.
Acta Otorhinolaryngol Ital . 2016 Dec; 36(5):345-367. PMID: 27958595
Neurofibromatosis type 2 [NF2; MIM # 101000] is an autosomal dominant disorder characterised by the occurrence of vestibular schwannomas (VSs), schwannomas of other cranial, spinal and cutaneous nerves, cranial and...
10.
Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, et al.
Blood Cancer J . 2016 Sep; 6(9):e468. PMID: 27611921
Long non-coding RNAs (lncRNAs) represent a novel class of functional RNA molecules with an important emerging role in cancer. To elucidate their potential pathogenetic role in chronic lymphocytic leukemia (CLL),...